Optimal Management of Adverse Events from Copanlisib in the Treatment of Patients with Non-Hodgkin Lymphomas

Copanlisib, an intravenously administered agent with inhibitory activity that predominantly targets the alpha and delta isoforms of PI3K, was granted accelerated approval by the US Food and Drug Administration on the basis of its activity in the third-line treatment of follicular NHL. Copanlisib is associated with several potentially serious adverse conditions, some of which are not shared with other PI3K inhibitors (i.e. infusion-related hyperglycemia and hypertension). Education and guidance are needed to help physicians manage adverse effects associated with copanlisib treatment. Therefore, this panel developed recommendations and guidance for the optimal management of adverse events associated with copanlisib treatment in patients with follicular lymphoma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research